贝那普利和缬沙坦对高血压病患者促红细胞生成素水平的影响

Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension

目的比较缬沙坦和贝那普利对肾功能正常的高血压病患者促红细胞生成素(EPO)分泌及血红蛋白水平的影响。方法将60例高血压病患者随机分为缬沙坦组(n=30,缬沙坦80 mg/d)和贝那普利组(n=30,贝那普利10 mg/d)。连续用药8周,在用药前及用药后4和8周分别检测两组患者体内EPO、红细胞计数、血红蛋白等相关指标。结果两组患者血红蛋白和EPO等均在正常范围内。但缬沙坦有降低患者EPO和血红蛋白水平的趋势(P<0.05),贝纳普利组EPO和血红蛋白水平前后比较差异均无统计学意义(P>0.05)。结论缬沙坦有减少肾功能正常的高血压病患者EPO分泌和血红蛋白水平的趋势,其对于有贫血或贫血倾向的高血压病患者的安全性尚需研究。

Objective To compare effects of valsartan and benazepril on erythropoietin（EPO） levels in essential hypertensive patients with normal renal function.Methods Sixty essential hypertensive patients were randomly divided into valsartan group（n=30,valsartan 80 mg/day） and benazepril group（n=30,benazepril 10 mg/day）.Plasma EPO and hemoglobin（Hb） levels were measured at the start of and at 4 and 8 weeks during the treatments.Results EPO and Hb levels were all in normal range in the two groups.Valsartan decreased EPO levels from 14.179±3.214 U/L（baseline） to 12.138±2.926 U/L（P0.05） and Hb levels from 144.32±13.84 g/L（baseline） to 135.16±14.78 U/L（P0.05）.Benazepril treatment did not resulted in any obvious changes in EPO or Hb levels（P0.05）.Conclusion Valsartan may lower EPO and Hb levels in patients with essential hypertension,while benazepril does not have such effects.The safety of valsartan in anemic hypertensive patients should be further investigated.